Grifols, S.A. - Product Pipeline Review - 2015

  • ID: 3266312
  • Company Profile
  • 50 pages
  • Global Markets Direct
  • Grifols, S.A.
1 of 4
Grifols, S.A. - Product Pipeline Review - 2015

Summary

This, ‘Grifols, S.A. - Product Pipeline Review - 2015’, provides an overview of the Grifols, S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grifols, S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Grifols, S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Grifols, S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Grifols, S.A.’s pipeline products

Reasons to buy

- Evaluate Grifols, S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Grifols, S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Grifols, S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Grifols, S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grifols, S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Grifols, S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Grifols, S.A. Snapshot
Grifols, S.A. Overview
Key Information
Key Facts
Grifols, S.A. – Research and Development Overview
Key Therapeutic Areas
Grifols, S.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Partnered Products
Partnered Products/Combination Treatment Modalities
Grifols, S.A. – Pipeline Products Glance
Grifols, S.A. – Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Grifols, S.A. – Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Phase 0 Products/Combination Treatment Modalities
Grifols, S.A. – Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Grifols, S.A. - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Grifols, S.A. – Drug Profiles
albumin (human)
Product Description
Mechanism of Action
R&D Progress
ARD-3150
Product Description
Mechanism of Action
R&D Progress
immune globulin (human)
Product Description
Mechanism of Action
R&D Progress
Recombinant A1PI
Product Description
Mechanism of Action
R&D Progress
Human Plasmin
Product Description
Mechanism of Action
R&D Progress
fibrinogen concentrate (human)
Product Description
Mechanism of Action
R&D Progress
ARD-3100
Product Description
Mechanism of Action
R&D Progress
Human Coagulation Factor-VIII (Recombinant)
Product Description
Mechanism of Action
R&D Progress
Recombinant Plasmin
Product Description
Mechanism of Action
R&D Progress
Grifols, S.A. – Pipeline Analysis
Grifols, S.A. – Pipeline Products by Target
Grifols, S.A. – Pipeline Products by Route of Administration
Grifols, S.A. – Pipeline Products by Molecule Type
Grifols, S.A. – Pipeline Products by Mechanism of Action
Grifols, S.A. – Recent Pipeline Updates
Grifols, S.A. – Dormant Projects
Grifols, S.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Grifols, S.A., Key Information
Grifols, S.A., Key Facts
Grifols, S.A. – Pipeline by Indication, 2015
Grifols, S.A. – Pipeline by Stage of Development, 2015
Grifols, S.A. – Monotherapy Products in Pipeline, 2015
Grifols, S.A. – Partnered Products in Pipeline, 2015
Grifols, S.A. – Partnered Products/ Combination Treatment Modalities, 2015
Grifols, S.A. – Phase III, 2015
Grifols, S.A. – Phase II, 2015
Grifols, S.A. – Phase I, 2015
Grifols, S.A. – Phase 0, 2015
Grifols, S.A. – Preclinical, 2015
Grifols, S.A. – Unknown, 2015
Grifols, S.A. – Pipeline by Target, 2015
Grifols, S.A. – Pipeline by Route of Administration, 2015
Grifols, S.A. – Pipeline by Molecule Type, 2015
Grifols, S.A. – Pipeline Products by Mechanism of Action, 2015
Grifols, S.A. – Recent Pipeline Updates, 2015
Grifols, S.A. – Dormant Developmental Projects,2015
Grifols, S.A., Other Locations
Grifols, S.A., Subsidiaries

List of Figures
Grifols, S.A. – Pipeline by Top 10 Indication, 2015
Grifols, S.A. – Pipeline by Stage of Development, 2015
Grifols, S.A. – Monotherapy Products in Pipeline, 2015
Grifols, S.A. – Pipeline by Top 10 Target, 2015
Grifols, S.A. – Pipeline by Top 10 Route of Administration, 2015
Grifols, S.A. – Pipeline by Top 10 Molecule Type, 2015
Grifols, S.A. – Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll